---
title: "Impact of elexacaftor-tezacaftor-ivacaftor on lung function trajectories in children with cystic f"
id: "medrxiv-10-lung-function-trajectories-in-children-with-cystic-fibrosis-aged-3-17-years"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-10-lung-function-trajectories-in-children-with-cystic-fibrosis-aged-3-17-years"
content_type: "clinical_feed_article"
specialty: "Pulmonology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361791v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Impact of elexacaftor-tezacaftor-ivacaftor on lung function trajectories in children with cystic f
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-10-lung-function-trajectories-in-children-with-cystic-fibrosis-aged-3-17-years
- **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361791v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This prospective observational study assessed lung function trajectories in children aged 3–17 years with **cystic fibrosis** before and after starting **elexacaftor-tezacaftor-ivacaftor (ETI)** using lung clearance index (LCI). - Children with at least two LCI tests before and two after ETI were used to model trajectories; those with at least one pre- and one post-ETI LCI were used to estimate acute change. - Age-adjusted LCI trajectories for pre-ETI and post-ETI periods were estimated with linear mixed-effects models; paired Wilcoxon tests compared pre- and post-ETI LCI values. - Mean longitudinal change in LCI before ETI was −0.007 turnovers/year (95% CI −0.28 to 0.27; n=35) and after ETI was 0.12 turnovers/year (95% CI −0.17 to 0.41; n=20). - The proportion of patients with impaired LCI (≥7.1 turnovers) decreased from 57% (30/53) pre-ETI to 26% (14/53) post-ETI. - Median LCI difference pre- versus post-ETI was −0.70 turnovers (95% CI −0.84 to −0.46), p<0.001, indicating an acute improvement in LCI after ETI initiation. - Within-individual variability in LCI measurements declined after starting ETI, suggesting greater stability of lung function up to three years post-initiation. - The study reports real-world, longitudinal evidence of both an acute improvement in **LCI** and maintained stability in LCI trajectories following **ETI** initiation. - Ethics approval was obtained from Children's Health Queensland HREC [HREC/19/QCHC/51727]. Funding sources included the Cystic Fibrosis Foundation (USA), Children's Hospital Foundation, and the National Health and Medical Research Council (grant 1193840).
## Clinical Analysis & Structured Key Points
Lung function trajectories in children with cystic fibrosis aged 3-17 years: impact of elexacaftor-tezacaftor-ivacaftor on lung function | medRxiv Skip to main content Lung function trajectories in children with cystic fibrosis aged 3-17 years: impact of elexacaftor-tezacaftor-ivacaftor on lung function Brett Paul Dyer , Maddy Deery , Rebecca Heyman , Paul Robinson , Claire Wainwright , Peter Sly , Robert Ware , Tamara Blake doi: https://doi.org/10.64898/2026.08.31.26361791 Brett Paul Dyer 1 Griffith Biostatistics Unit, Griffith Health, Griffith University, Gold Coast, Queensland, Australia. Wesley Research Institute, Brisbane, Queensland, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: b.dyer{at}griffith.edu.au Maddy Deery 2 Children's Health and Environment Program, Child Health Research Centre, University of Queensland, South Brisbane, Queensland, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rebecca Heyman 2 Children's Health and Environment Program, Child Health Research Centre, University of Queensland, South Brisbane, Queensland, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Paul Robinson 3 Childrens Health and Environment Program, Child Health Research Centre, University of Queensland, South Brisbane, Queensland, Australia. Department of Respiratory and Sleep Medicine, Queensland Childrens Hospital, South Brisbane, Queensland, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Claire Wainwright 4 Department of Respiratory and Sleep Medicine, Queensland Childrens Hospital, South Brisbane, Queensland, Australia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Peter Sly 3 Childrens Health and Environment Program, Child Health Research Centre, University of Queensland, South Brisbane, Queensland, Australia. Department of Respiratory and Sleep Medicine, Queensland Childrens Hospital, South Brisbane, Queensland, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Robert Ware 1 Griffith Biostatistics Unit, Griffith Health, Griffith University, Gold Coast, Queensland, Australia. Wesley Research Institute, Brisbane, Queensland, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tamara Blake 3 Childrens Health and Environment Program, Child Health Research Centre, University of Queensland, South Brisbane, Queensland, Australia. Department of Respiratory and Sleep Medicine, Queensland Childrens Hospital, South Brisbane, Queensland, Australia; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background Elexacaftor-tezacaftor-ivacaftor (ETI) has been demonstrated to improve lung function in clinical trials; however, evidence describing effects on trajectories and whether long-term improvements are sustained (>1-year) is lacking. We estimated within-person lung clearance index (LCI) trajectories before and after ETI initiation, assessing changes in level and rate of change, alongside acute LCI change, up to three years after ETI initiation. Methods Prospective observational study of children at a tertiary hospital. Children aged 3-17 years with ≥2 LCI testing occasions (i) before and (ii) after starting ETI were used to describe lung function trajectories. Children with ≥1 pre-ETI and ≥1 post-ETI LCI occasion(s) were used to describe acute LCI change after ETI initiation. Age-adjusted LCI trajectories for time periods (i) before and (ii) after ETI initiation were estimated using linear mixed-effects models, and pre- and post-ETI LCIs were compared using paired Wilcoxon tests. Results Mean pre-ETI and post-ETI longitudinal changes in LCI were -0.007 (95% CI: -0.28, 0.27; n=35) and 0.12 (95% CI: -0.17, 0.41; n=20) turnovers per year, respectively. Before ETI initiation, 57% (30/53) of patients had an LCI≥7.1 turnovers (indicating impaired lung function), compared to 26% (14/53) post-ETI, with a median LCI difference of -0.70 (95% CI -0.84, -0.46; p<0.001) turnovers. Within-individual variability in LCI decreased post-ETI. Conclusions Our real-world data within a unique longitudinal study provide a comprehensive picture of ETI benefit by outlining not only acute improvement in LCI but maintained stability in LCI trajectories and improved LCI stability sustained up to three years post-initiation. Competing Interest Statement CW has disclosed competing interests in the uploaded ICMJE disclosure form. The other authors do not have competing interests to declare. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by Children's Health Queensland (CHQ) Human Research Ethics Committee (HREC) [HREC/19/QCHC/51727] I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Funder Information Declared Cystic Fibrosis Foundation , USA SLY18KO Children's Hospital Foundation, https://ror.org/03g60bf21 National Health and Medical Research Council , 1193840 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Lung function trajectories in children with cystic fibrosis aged 3-17 years: impact of elexacaftor-tezacaftor-ivacaftor on lung function Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Lung function trajectories in children with cystic fibrosis aged 3-17 years: impact of elexacaftor-tezacaftor-ivacaftor on lung function Brett Paul Dyer , Maddy Deery , Rebecca Heyman , Paul Robinson , Claire Wainwright , Peter Sly , Robert Ware , Tamara Blake medRxiv 2026.08.31.26361791; doi: https://doi.org/10.64898/2026.08.31.26361791 Share This Article: Copy Citation Tools Lung function trajectories in children with cystic fibrosis aged 3-17 years: impact of elexacaftor-tezacaftor-ivacaftor on lung function Brett Paul Dyer , Maddy Deery , Rebecca Heyman , Paul Robinson , Claire Wainwright , Peter Sly , Robert Ware , Tamara Blake medRxiv 2026.08.31.26361791; doi: https://doi.org/10.64898/2026.08.31.26361791 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Respiratory Medicine Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (896) Anesthesia (326) Cardiovascular Medicine (4770) Dentistry and Oral Medicine (474) Dermatology (407) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1614) Epidemiology (15835) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6983) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4982) Health Policy (1426) Health Systems and Quality Improvement (1736) Hematology (581) HIV/AIDS (1336) Infectious Diseases (except HIV/AIDS) (16244) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (720) Neurology (7194) Nursing (363) Nutrition (1074) Obstetrics and Gynecology (1231) Occupational and Environmental Health (1001) Oncology (3573) Ophthalmology (1036) Orthopedics (393) Otolaryngology (446) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1772) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5832) Public and Global Health (9691) Radiology and Imaging (2387) Rehabilitation Medicine and Physical Therapy (1432) Respiratory Medicine (1241) Rheumatology (633) Sexual and Reproductive Health (766) Sports Medicine (576) Surgery (766) Toxicology (107) Transplantation (303) Urology (286)
## Related Clinical Research

- [Triglyceride-Glucose (TyG) Index and Mortality in Non-Diabetic Fibrotic Lung Disease on Antifibrot](https://medichelpline.com/clinical-feed/plos-one-1-association-between-triglyceride-glucose-index-and-all-cause-mortality-in-non.md)
- [Pemafibrate as a senotherapeutic for COPD via TFEB-driven autophagy and mitophagy regulation](https://medichelpline.com/clinical-feed/medrxiv-4-senotherapeutic-role-of-pemafibrate-through-autophagy-mitophagy-regulation-in.md)
- [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md)
- [Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation](https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an.md)
- [Readers’ reactions: M.D. vs D.O., AI and physician autonomy, surrogacy, postpartum psychiatry, and](https://medichelpline.com/clinical-feed/stat-news-0-opinion-what-stat-readers-think-about-m-d-vs-d-o-ai-in-medicine-surrogacy-and.md)

## Navigation
- [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.